Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer

BACKGROUND: Nivolumab offers a superior survival benefit over docetaxel in patients with advanced, previously treated non-small-cell lung cancer (NSCLC). An association between programmed cell death ligand-1 (PD-L1) expression and the efficacy of nivolumab has been reported in many studies. However,...

Descripción completa

Detalles Bibliográficos
Autores principales: Oya, Yuko, Yoshida, Tatsuya, Kuroda, Hiroaki, Mikubo, Masashi, Kondo, Chiaki, Shimizu, Junichi, Horio, Yoshitsugu, Sakao, Yukinori, Hida, Toyoaki, Yatabe, Yasushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732716/
https://www.ncbi.nlm.nih.gov/pubmed/29262550
http://dx.doi.org/10.18632/oncotarget.21602

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732716/
https://www.ncbi.nlm.nih.gov/pubmed/29262550
http://dx.doi.org/10.18632/oncotarget.21602

Ejemplares similares